Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant
Thien B Tran1,2, Jiping Wang1,2, Yohei Doi3
1Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
Abstract:
Due to limited new antibiotics, polymyxins are increasingly used to treat multidrug-resistant (MDR) Gram-negative bacteria, in particular carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Unfortunately, polymyxin monotherapy has led to the emergence of resistance. Polymyxin combination therapy has been demonstrated to improve bacterial killing and prevent the emergence of resistance. From a preliminary screening of an FDA drug library, we identified antineoplastic mitotane as a potential candidate for combination therapy with polymyxin B against polymyxin-resistant Gram-negative bacteria. Here, we demonstrated that the combination of polymyxin B with mitotane enhances the in vitro antimicrobial activity of polymyxin B against 10 strains of A. baumannii, P. aeruginosa, and K. pneumoniae, including polymyxin-resistant MDR clinical isolates. Time-kill studies showed that the combination of polymyxin B (2 mg/L) and mitotane (4 mg/L) provided superior bacterial killing against all strains during the first 6 h of treatment, compared to monotherapies, and prevented regrowth and emergence of polymyxin resistance in the polymyxin-susceptible isolates. Electron microscopy imaging revealed that the combination potentially affected cell division in A. baumannii. The enhanced antimicrobial activity of the combination was confirmed in a mouse burn infection model against a polymyxin-resistant A. baumannii isolate. As mitotane is hydrophobic, it was very likely that the synergistic killing of the combination resulted from that polymyxin B permeabilized the outer membrane of the Gram-negative bacteria and allowed mitotane to enter bacterial cells and exert its antimicrobial effect. These results have important implications for repositioning non-antibiotic drugs for antimicrobial purposes, which may expedite the discovery of novel therapies to combat the rapid emergence of antibiotic resistance.
Insights
Combining polymyxin B with the cancer drug mitotane enhances killing of multidrug-resistant (MDR) Gram-negative bacteria. This combination therapy shows promise in preventing antibiotic resistance and offers a new strategy against challenging infections.
Area of Science:
- Infectious Diseases
- Antimicrobial Resistance
- Pharmacology
Background:
- Polymyxins are crucial for treating multidrug-resistant (MDR) Gram-negative bacterial infections due to limited new antibiotic development.
- Polymyxin monotherapy leads to resistance; combination therapy improves efficacy and prevents resistance emergence.
- Identifying novel antimicrobial agents is critical to combatting the rise of antibiotic resistance.
Purpose of the Study:
- To evaluate the antineoplastic drug mitotane as a potential combination therapy with polymyxin B against polymyxin-resistant Gram-negative bacteria.
- To investigate the synergistic antimicrobial activity and resistance-preventing potential of polymyxin B-mitotane combination therapy.
Main Methods:
- Screened an FDA drug library to identify potential combination partners for polymyxin B.
- Tested the combination of polymyxin B and mitotane against clinical isolates of carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
- Conducted time-kill studies, electron microscopy, and a mouse burn infection model to assess efficacy and mechanism.
Main Results:
- The combination of polymyxin B and mitotane demonstrated enhanced in vitro antimicrobial activity against 10 MDR Gram-negative bacterial strains, including polymyxin-resistant isolates.
- The combination provided superior bacterial killing within 6 hours and prevented resistance emergence in susceptible isolates.
- Electron microscopy suggested the combination may interfere with bacterial cell division, and in vivo studies confirmed efficacy in a mouse model.
Conclusions:
- Polymyxin B combined with mitotane exhibits significant synergistic antimicrobial activity against MDR Gram-negative bacteria.
- This combination effectively enhances bacterial killing and prevents the emergence of polymyxin resistance.
- Repurposing non-antibiotic drugs like mitotane offers a promising strategy to develop novel therapies against antibiotic-resistant infections.
Related Concept Videos
Gram-negative Bacterial Protein Secretion Systems
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...


